AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31382934 — intervention group
Group type: COMPARATOR
Intervention: Dissection directly on the inferior mesenteric artery (IMA)
Number of subjects: 90
Study 31382934 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 90
Study 28301859 — intervention group
Group type: EXPERIMENTAL
Intervention: Social learning and cognitive behavioral therapy in-person (SLCBT)
Number of subjects: 316
Study 28301859 — intervention group
Group type: EXPERIMENTAL
Intervention: Social learning and cognitive behavioral therapy by phone (SLCBT-R)
Number of subjects: 316
Study 28301859 — intervention group
Group type: COMPARATOR
Intervention: Education and support condition by phone (ES-R)
Number of subjects: 316
Study 28301859 — intervention group
Group type: EXPERIMENTAL
Intervention: Social learning and cognitive behavioral therapy (remote condition only)
Number of subjects: 316
Study 28301859 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-reported functional disability
Number of subjects: 316
Study 28301859 — intervention group
Group type: EXPERIMENTAL
Intervention: Child health care visits for abdominal pain
Number of subjects: 316
Study 27532830 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop therapy
Number of subjects: 16
Study 27532830 — intervention group
Group type: COMPARATOR
Intervention: Control therapy (sensor-augmented pump therapy)
Number of subjects: 16
Study 27532830 — intervention group
Group type: COMPARATOR
Intervention: Closed-loop therapy and Control therapy
Number of subjects: 16
Study 24773243 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 87
Study 24773243 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study 21979301 — intervention group
Group type: EXPERIMENTAL
Intervention: Prulifloxacin (600 mg daily for 14 days) + FERTIMEV (1 vial daily for 6 months)
Number of subjects: 206
Study 21979301 — intervention group
Group type: COMPARATOR
Intervention: Prulifloxacin (600 mg daily for 14 days)
Number of subjects: 206
Study 19712493 — intervention group
Group type: EXPERIMENTAL
Intervention: NIV with heliox
Number of subjects: 12
Study 19712493 — intervention group
Group type: COMPARATOR
Intervention: Heliox with sham NIV
Number of subjects: 12
Study 19712493 — intervention group
Group type: COMPARATOR
Intervention: NIV alone
Number of subjects: 12
Study 19712493 — intervention group
Group type: COMPARATOR
Intervention: Heliox
Number of subjects: 12
Study 19712493 — intervention group
Group type: COMPARATOR
Intervention: Sham NIV
Number of subjects: 12
Study 17715631 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated interferon α-2a and ribavirin
Number of subjects: 2
Study 17715631 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 2
Study 15041614 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% sevoflurane
Number of subjects: 20
Study 15041614 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5% sevoflurane
Number of subjects: 20
Study 11309826 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh Frozen Plasma (FFP)
Number of subjects: 27
Study 11309826 — intervention group
Group type: COMPARATOR
Intervention: Cryoprecipitate Poor Plasma (CPP)
Number of subjects: 27
Study 9131703 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based 'Fat Watch' campaign
Number of subjects: 500
Study 9131703 — intervention group
Group type: COMPARATOR
Intervention: Control community
Number of subjects: 500
Study 8239223 — intervention group
Group type: EXPERIMENTAL
Intervention: Zileuton 2.4 g/d
Number of subjects: 139
Study 8239223 — intervention group
Group type: EXPERIMENTAL
Intervention: Zileuton 1.6 g/d
Number of subjects: 139
Study 8239223 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 139
Study 3311755 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (15 mg i.v. followed by 200 mg day‐1 orally)
Number of subjects: 61
Study 3311755 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 61
Study 29880727 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary protein intake
Number of subjects: 0
Study 29880727 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast feeding
Number of subjects: 0
Study 29880727 — intervention group
Group type: EXPERIMENTAL
Intervention: Human milk feeding
Number of subjects: 0
Study 27012726 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor control training intervention (15 weeks, 8 weeks)
Number of subjects: 46
Study 27012726 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor control training intervention for players with current LBP
Number of subjects: 46
Study 27012726 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group (7 weeks intervention)
Number of subjects: 46
Study 25108907 — intervention group
Group type: COMPARATOR
Intervention: HTO with platelet-rich plasma (PRP) injection only (n = 23)
Number of subjects: 44
Study 25108907 — intervention group
Group type: EXPERIMENTAL
Intervention: HTO with MSC therapy and PRP injection (n = 21)
Number of subjects: 44
Study 23441529 — intervention group
Group type: EXPERIMENTAL
Intervention: Methoxy polyethylene glycol-epoetin beta (CERA) at recommended dose (104.33 mcg/month)
Number of subjects: 79
Study 23441529 — intervention group
Group type: COMPARATOR
Intervention: Methoxy polyethylene glycol-epoetin beta (CERA) at alternative dose (113.08 mcg/month)
Number of subjects: 79
Study 21191167 — intervention group
Group type: EXPERIMENTAL
Intervention: Home telecare intervention
Number of subjects: 0
Study 19202954 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose atorvastatin
Number of subjects: 0
Study 19202954 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tissue plasminogen activator
Number of subjects: 0
Study 19202954 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted-dose warfarin
Number of subjects: 0
Study 19202954 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin once daily
Number of subjects: 0
Study 19202954 — intervention group
Group type: COMPARATOR
Intervention: Carotid angioplasty/stenting vs. endarterectomy
Number of subjects: 0
Study 15926135 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin at doses of 150 mg to 600 mg per day
Number of subjects: 1052
Study 15926135 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin at 600 mg per day
Number of subjects: 1052
Study 15926135 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 1052
Study 15926135 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1052
Study 12566019 — intervention group
Group type: EXPERIMENTAL
Intervention: FDT perimetry
Number of subjects: 307
Study 12566019 — intervention group
Group type: EXPERIMENTAL
Intervention: Polarimetry (GDx)
Number of subjects: 307
Study 12566019 — intervention group
Group type: EXPERIMENTAL
Intervention: FDT and GDx combined
Number of subjects: 307
Study 12566019 — intervention group
Group type: COMPARATOR
Intervention: GDx
Number of subjects: 307
Study 12920842 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anesthesia (group EA, n = 16)
Number of subjects: 32
Study 12920842 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia (group GA, n = 16)
Number of subjects: 32
Study 9861552 — intervention group
Group type: COMPARATOR
Intervention: Methylphenidate (5.0-30.0 mg)
Number of subjects: 17
Study 9861552 — intervention group
Group type: COMPARATOR
Intervention: d-Amphetamine (2.5-20.0 mg)
Number of subjects: 17
Study 9861552 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate and d-Amphetamine
Number of subjects: 17
Study 7879963 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrophilic guidewires
Number of subjects: 33
Study 7879963 — intervention group
Group type: COMPARATOR
Intervention: Conventional guidewires
Number of subjects: 33
Study 2244440 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat and moisture exchanger (HME) used in 10 patients
Number of subjects: 20
Study 2244440 — intervention group
Group type: COMPARATOR
Intervention: Control group (no HME) with 10 patients
Number of subjects: 20
Study 27463 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg mepindolol
Number of subjects: 16
Study 27463 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg propranolol
Number of subjects: 16
Study 27463 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg pindolol
Number of subjects: 16
Study 27463 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 30071142 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole Body Vibration (WBV), performed three times a week for 12 weeks
Number of subjects: 30
Study 30071142 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 29284465 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (3 times per week)
Number of subjects: 87
Study 29284465 — intervention group
Group type: COMPARATOR
Intervention: Donepezil hydrochloride (5 mg/day for first 4 weeks, then 10 mg/day thereafter)
Number of subjects: 87
Study 25544195 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypericum 900-1500 mg/day
Number of subjects: 340
Study 25544195 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline 50-100 mg/day
Number of subjects: 340
Study 25544195 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 340
Study 23358929 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiation (CRT group; Arm 1) - EBRT to pelvis (45 Gy) with concurrent oral Capecitabine
Number of subjects: 90
Study 23358929 — intervention group
Group type: COMPARATOR
Intervention: Radiation therapy with boost (RT with boost group; Arm 2) - EBRT to pelvis (45 Gy) alone followed by 20 Gy localized radiotherapy boost
Number of subjects: 90
Study 21307717 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 0.15 mg/kg every 6 hours for 4 days
Number of subjects: 49
Study 21307717 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 19821654 — intervention group
Group type: EXPERIMENTAL
Intervention: BIAsp 30
Number of subjects: 480
Study 19821654 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 480
Study 17080281 — intervention group
Group type: EXPERIMENTAL
Intervention: Z-plasty repair
Number of subjects: 72
Study 17080281 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgery (delayed healing by secondary intention)
Number of subjects: 72
Study 15636229 — intervention group
Group type: EXPERIMENTAL
Intervention: Scanning laser polarimetry (NFA/GDx, software version 1.0.16)
Number of subjects: 28
Study 15636229 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard automated perimetry (SAP-HFA, 24-2 threshold test)
Number of subjects: 28
Study 11728676 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil citrate (Viagra) 50 mg for 2 weeks, increased to 100 mg if needed; duration of treatment was 12 weeks.
Number of subjects: 60
Study 11728676 — intervention group
Group type: COMPARATOR
Intervention: Placebo; duration of treatment was 12 weeks.
Number of subjects: 60
Study 9234024 — intervention group
Group type: EXPERIMENTAL
Intervention: Cafetiere coffee (5-6 cups/day)
Number of subjects: 63
Study 9234024 — intervention group
Group type: EXPERIMENTAL
Intervention: Coffee oil (equivalent to 10-20 cups of unfiltered coffee)
Number of subjects: 63
Study 9234024 — intervention group
Group type: EXPERIMENTAL
Intervention: Purified mixture of cafestol and kahweol
Number of subjects: 63
Study 9234024 — intervention group
Group type: EXPERIMENTAL
Intervention: Cafestol (10 mg/d)
Number of subjects: 63
Study 8354108 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 micrograms
Number of subjects: 206
Study 8354108 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 micrograms
Number of subjects: 206
Study 8354108 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 micrograms
Number of subjects: 206
Study 8354108 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 micrograms (1 year after primary immunization)
Number of subjects: 206
Study 8354108 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 micrograms (1 year after primary immunization)
Number of subjects: 206
Study 8354108 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 micrograms (1 year after primary immunization)
Number of subjects: 206
Study 3497379 — intervention group
Group type: EXPERIMENTAL
Intervention: Orally administered amoxicillin
Number of subjects: 83
Study 3497379 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study 31677985 — intervention group
Group type: EXPERIMENTAL
Intervention: Suction (S)
Number of subjects: 0
Study 31677985 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-pull (SP)
Number of subjects: 0
Study 30077969 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT)
Number of subjects: 56
Study 30077969 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Number of subjects: 56
Study 29216937 — intervention group
Group type: EXPERIMENTAL
Intervention: PPI group (PPI < 1.4 for diagnosis, PPI > 2 for treatment)
Number of subjects: 73
Study 29216937 — intervention group
Group type: EXPERIMENTAL
Intervention: PPI group
Number of subjects: 73
Study 29216937 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 73
Study 25363415 — intervention group
Group type: EXPERIMENTAL
Intervention: Tarafenacin 0.4 mg
Number of subjects: 235
Study 25363415 — intervention group
Group type: EXPERIMENTAL
Intervention: Tarafenacin 0.2 mg
Number of subjects: 235
Study 25363415 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 235
Study 25363415 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 235
Study 25363415 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 235
Study 23248234 — intervention group
Group type: EXPERIMENTAL
Intervention: Cheese and vegetables (combined snack)
Number of subjects: 201
Study 23248234 — intervention group
Group type: COMPARATOR
Intervention: Potato chips (control)
Number of subjects: 201
Study 21306309 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain-sparing flow (defined as a middle cerebral artery-to-umbilical artery pulsatility index ratio of <1.08)
Number of subjects: 126
Study 21306309 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain-sparing flow
Number of subjects: 126
Study 19348537 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotionally neutral faces perceived to possess various personality traits
Number of subjects: 0
Study 17845648 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine (40 ml)
Number of subjects: 27
Study 17845648 — intervention group
Group type: COMPARATOR
Intervention: 4% lidocaine (40 ml)
Number of subjects: 27
Study 15050863 — intervention group
Group type: EXPERIMENTAL
Intervention: Vagus nerve stimulation with pulse width 250 micros
Number of subjects: 12
Study 15050863 — intervention group
Group type: EXPERIMENTAL
Intervention: Vagus nerve stimulation with pulse width 500 micros
Number of subjects: 12
Study 15050863 — intervention group
Group type: EXPERIMENTAL
Intervention: Vagus nerve stimulation with pulse width 130 micros
Number of subjects: 12
Study 11383646 — intervention group
Group type: EXPERIMENTAL
Intervention: Our formula: MHE=13.2 D/W(0.5)
Number of subjects: 104
Study 11383646 — intervention group
Group type: COMPARATOR
Intervention: Heiken's formula: MHE=CD/W
Number of subjects: 104
Study 9587911 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic exposure to carbon disulfide (9.36‐23.4 mg/m2)
Number of subjects: 65
Study 9587911 — intervention group
Group type: COMPARATOR
Intervention: Control group (not exposed to carbon disulfide)
Number of subjects: 65
Study 7912539 — intervention group
Group type: EXPERIMENTAL
Intervention: BRL35135 8 mg
Number of subjects: 8
Study 7912539 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol 8 mg
Number of subjects: 8
Study 7912539 — intervention group
Group type: COMPARATOR
Intervention: Nadolol 20 mg
Number of subjects: 8
Study 7912539 — intervention group
Group type: COMPARATOR
Intervention: Bisoprolol 5 mg
Number of subjects: 8
Study 2645808 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg/kg midazolam with 0.015-0.02 mg/kg atropine (Group I)
Number of subjects: 80
Study 2645808 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg midazolam with 0.015-0.02 mg/kg atropine (Group II)
Number of subjects: 80
Study 2645808 — intervention group
Group type: COMPARATOR
Intervention: Comparison of both groups
Number of subjects: 80
Study 53330 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine (2-5 mg twice daily)
Number of subjects: 3
Study 53330 — intervention group
Group type: COMPARATOR
Intervention: Quinoestrol (4 mg single dose)
Number of subjects: 3
Study 53330 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study 30548573 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma-hydroxybutyric acid (GHB) administration
Number of subjects: 20
Study 30548573 — intervention group
Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 20
Study 27923500 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative educational telephone call
Number of subjects: 104
Study 27923500 — intervention group
Group type: COMPARATOR
Intervention: No preoperative educational telephone call (Control)
Number of subjects: 104
Study 25533903 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (EX)
Number of subjects: 22
Study 23419004 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 20
Study 23419004 — intervention group
Group type: COMPARATOR
Intervention: Tryptophan-balanced control condition (BAL)
Number of subjects: 20
Study 21521895 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mL deionized water
Number of subjects: 80
Study 21521895 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.7% w/v citric acid
Number of subjects: 80
Study 21521895 — intervention group
Group type: EXPERIMENTAL
Intervention: Seltzer water
Number of subjects: 80
Study 21521895 — intervention group
Group type: EXPERIMENTAL
Intervention: 50:50 diluted ethanol/water
Number of subjects: 80
Study 21521895 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age group (60+ years)
Number of subjects: 80
Study 21521895 — intervention group
Group type: EXPERIMENTAL
Intervention: Supertasters
Number of subjects: 80
Study 18444872 — intervention group
Group type: EXPERIMENTAL
Intervention: CPG 7909 adjuvant plus HBV vaccine
Number of subjects: 38
Study 18444872 — intervention group
Group type: COMPARATOR
Intervention: Control group (HBV vaccine without CPG 7909)
Number of subjects: 38
Study 17058781 — intervention group
Group type: EXPERIMENTAL
Intervention: Non verbal instruction
Number of subjects: 120
Study 17058781 — intervention group
Group type: COMPARATOR
Intervention: Verbal instruction
Number of subjects: 120
Study 12574791 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquorice consumption (100 g daily for 4 weeks, 150 mg glycyrrhetinic acid)
Number of subjects: 0
Study 10959541 — intervention group
Group type: EXPERIMENTAL
Intervention: d-amphetamine (AMP; 10 and 20 mg)
Number of subjects: 37
Study 10959541 — intervention group
Group type: EXPERIMENTAL
Intervention: ethanol (EtOH; 0.2, 0.4, and 0.8 g/kg)
Number of subjects: 37
Study 9379784 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg oral buspirone
Number of subjects: 6
Study 9379784 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg oral buspirone
Number of subjects: 6
Study 9379784 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 1588521 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise-based rehabilitation programme with advice about return to normal activity
Number of subjects: 110
Study 1588521 — intervention group
Group type: COMPARATOR
Intervention: Standard hospital care (Control)
Number of subjects: 110
Study 3898825 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mcg vaccine
Number of subjects: 43
Study 3898825 — intervention group
Group type: COMPARATOR
Intervention: 40 mcg vaccine
Number of subjects: 43
Study 3898825 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mcg vaccine (normal volunteers)
Number of subjects: 43
Study 30287107 — intervention group
Group type: EXPERIMENTAL
Intervention: Multipoint percutaneous ethanol injection (MPEI)
Number of subjects: 117
Study 30287107 — intervention group
Group type: COMPARATOR
Intervention: Super-selective angiograms followed by embolization with gelfoam (EFAG) plus MPEI
Number of subjects: 117
Study 29231216 — intervention group
Group type: EXPERIMENTAL
Intervention: Aronia-citrus juice (ACJ) intake (200 mL per day for 45 days)
Number of subjects: 16
Study 29231216 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 16
Study 26478208 — intervention group
Group type: EXPERIMENTAL
Intervention: escitalopram 10 mg/day + single-dose i.v. ketamine (0.5 mg/kg over 40 min)
Number of subjects: 30
Study 26478208 — intervention group
Group type: COMPARATOR
Intervention: escitalopram 10 mg/day + placebo (0.9% i.v. saline)
Number of subjects: 30
Study 25199862 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-submerged implants
Number of subjects: 20
Study 25199862 — intervention group
Group type: COMPARATOR
Intervention: Submerged implants
Number of subjects: 20
Study 23109700 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture plus usual care
Number of subjects: 302
Study 23109700 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 302
Study 19795111 — intervention group
Group type: EXPERIMENTAL
Intervention: p.m.-a.m. group (sleep included)
Number of subjects: 0
Study 19795111 — intervention group
Group type: COMPARATOR
Intervention: a.m.-p.m. group (no sleep)
Number of subjects: 0
Study 19795111 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (young and old)
Number of subjects: 0
Study 17593904 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose beverage (50 g)
Number of subjects: 28
Study 17593904 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose beverage (50 g)
Number of subjects: 28
Study 17593904 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein beverage (50 g)
Number of subjects: 28
Study 17593904 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey + Fructose beverage (25 g each)
Number of subjects: 28
Study 17593904 — intervention group
Group type: COMPARATOR
Intervention: Energy intake after 4 h (all beverages)
Number of subjects: 28
Study 14999213 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback treatment (6 sessions of abdominal breath training, heart and respiratory physiologic feedback, daily breathing practice)
Number of subjects: 63
Study 14999213 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (control group)
Number of subjects: 63